Michelle A. Fravel

Michelle A. Fravel

Auto-generated profile, based on publicly available information

Michelle A. Fravel

Department of Pharmacy Practice and Science, College of Pharmacy The University of Iowa Iowa City Iowa USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
MFMichelle A. Fravel
Michelle A. Fravel
MEMichael Ernst
Michael Ernst

14 December 2021 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
JBJonathan C. Broder
Jonathan C. Broder
JRJoanne Ryan
Joanne Ryan
RSRaj C. Shah
Raj C. Shah
JLJessica E. Lockery
Jessica E. Lockery
Suzanne G OrchardSuzanne G Orchard
Suzanne G Orchard
MEMichael E. Ernst
Michael E. Ernst

21 February 2021 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
AGAlice Gahbauer
Alice Gahbauer
KGKatherine Gruenberg
Katherine Gruenberg
CFCatherine Forrester
Catherine Forrester
ASAmir Saba
Amir Saba
SSSamuel Schauer
Samuel Schauer
TBTina Brock
Tina Brock

30 April 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CBChad Bousman
Chad Bousman
ANAnkita Narang
Ankita Narang
ZBZiad Al Bkhetan
Ziad Al Bkhetan
RWRobyn Lorraine Woods
Robyn Lorraine Woods
Suzanne G OrchardSuzanne G Orchard
Suzanne G Orchard
MEMichael E. Ernst
Michael E. Ernst
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a change to standard prescribing), the use of cautionary medications (i.e., those associated with an actionable PGx genotype), polypharmacy (i.e., ≥ 5 medications simultaneously), and cytochrome P450 enzyme inhibitor and inducer use among 13,670 older adults enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Genotyping was conducted for 10 pharmacogenes with actionable PGx‐based prescribing guidelines. Medication data were collected annually and assessed to identify cautionary medication use in the cohort. Most participants (98.8%) carried at least one actionable PGx genotype, with an average of three actionable genotypes per participant. VKORC1 (61.1%) and CYP2C19 (59.6%) were the most frequently observed genes with actionable genotypes. Statins (29.3%), nonsteroidal anti‐inflammatory drugs (14.2%), and proton‐pump inhibitors (7.9%) were the most used cautionary medications, with 27.5% of participants taking at least one medication for which PGx guidelines recommended a deviation from standard prescribing. Most (83.9%) participants reported taking a polypharmacy regimen, and 68.2% reported use of at least one cytochrome P450 enzyme inhibitor or inducer during the trial. Our findings underscore the high prevalence of actionable PGx genotypes, polypharmacy, and use of inhibitors and inducers in older adults, which collectively have the potential to inform safer and more effective prescribing practices.

1 June 2025 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
MFMichelle A. Fravel
Michelle A. Fravel
MEMichael E. Ernst
Michael E. Ernst
RWRobyn Lorraine Woods
Robyn Lorraine Woods
Suzanne G OrchardSuzanne G Orchard
Suzanne G Orchard
SGShiva Ganjali
Shiva Ganjali
ZZZhen Zhou
Zhen Zhou
BACKGROUND: The ability of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator to accurately assign 10-year atherosclerotic cardiovascular disease (ASCVD) risk in older individuals, including those aged ≥80 years, is unknown. This study compares PREVENT with the 2013 Pooled Cohort Equation (PCE) calculator for predicting 10-year ASCVD risk in a large cohort of older adults. METHODS: This was a prospective cohort study of adults without CVD from Australia and the United States aged ≥70 years (≥65 years, if US minorities). They were enrolled from 2010 to 2014 in the ASPREE trial (Aspirin in Reducing Events in the Elderly), a 5-year randomized trial of low-dose aspirin in community-dwelling older adults with posttrial observational follow-up extending to 2022. ASCVD events were adjudicated by expert panels. The discriminative ability of the 2 risk calculators was assessed by Harell C statistic following Cox regression in the 65- to 79-year age group and >80-year age group, separately. For calibration, predicted event numbers were calculated using PREVENT and PCE, scaled for the actual length of follow-up, and compared with the number of observed events in-trial and during extended follow-up. RESULTS: Among the 15 510 participants aged 65 to 79 years (median age, 73.2 years; 56.1% women), 1084 ASCVD events occurred (median follow-up, 8.3 years); PCE predicted 3102 events while PREVENT predicted 1290 events. For the 2787 participants ≥80 years (median age, 82.6 years; 59.2% women), 355 ASCVD events occurred (median follow-up, 7.4 years); PCE predicted 1067 events while PREVENT predicted 350 events. PREVENT showed superior discriminative performance compared with PCE (PREVENT versus PCE, C statistic, 0.793 versus 0.740; P <0.001 in participants aged 65 –79 years; 0.854 versus 0.799; P <0.001 in those aged ≥80 years). CONCLUSIONS: The PREVENT risk calculator is superior to the PCE calculator in predicting ASCVD events in older adults from the United States and Australia, including those aged ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583. URL: https://www.isrctn.com ; Unique identifier: ISRCTN83772183.

20 November 2023 in Journal Of Hypertension
Verified
Journal Article
Closed access
MFMichelle A. Fravel
Michelle A. Fravel
MEMichael E. Ernst
Michael E. Ernst
RWRobyn L. Woods
Robyn L. Woods
LBLawrence Beilin
Lawrence Beilin
ZZZhen Zhou
Zhen Zhou
JRJoanne Ryan
Joanne Ryan
Introduction: In healthy older adults, the relationship between long-term, visit-to-visit variability in blood pressure (BP) and frailty is uncertain. Methods: Secondary analysis of blood pressure variability (BPV) and incident frailty in >13 000 participants ≥65–70 years enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial and its observational follow-up (ASPREE-XT). Participants were without dementia, physical disability, or cardiovascular disease at baseline. BPV was estimated using standard deviation of mean BP from three annual visits (baseline through the second annual follow-up). Frailty was defined using Fried phenotype and a frailty deficit accumulation index (FDAI). Participants with frailty during the BPV estimation period were excluded from the main analysis. Adjusted Cox proportional hazards regression evaluated the association between BPV and incident frailty, and linear mixed models for change in frailty scores, through a maximum of 9 years of follow-up. Results: Participants in the highest systolic BPV tertile were at higher risk of frailty compared to those in the lowest (referent) tertile of systolic BPV [Fried hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.04–1.31; FDAI HR 1.18, 95% CI 1.07–1.30]. Findings were consistent when adjusted for multiple covariates and when stratified by antihypertensive use. Linear mixed models showed that higher systolic BPV was associated with increasing frailty score over time. Diastolic BPV was not consistently associated. Conclusions: High systolic BPV, independent of mean BP, is associated with increased risk of frailty in healthy older adults. Variability of BP across visits, even in healthy older adults, can convey important risk information beyond mean BP. Trial Registration: ClinicalTrials.gov NCT01038583 and ISRCTN83772183